Halilibrahim Ciftci
Overview
Explore the profile of Halilibrahim Ciftci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reymova F, Sever B, Topalan E, Sevimli-Gur C, Can M, Tuyun A, et al.
Pharmaceuticals (Basel)
. 2025 Feb;
18(2).
PMID: 40006082
Despite recent breakthroughs in cancer treatment, non-small cell lung cancer (NSCLC) and breast cancer remain major causes of death from all malignancies. The epidermal growth factor receptor (EGFR) is an...
2.
Ciftci H, Otsuka M, Fujita M, Sever B
Turk J Chem
. 2025 Jan;
48(6):856-866.
PMID: 39780846
The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), pioneer members of the receptor tyrosine kinase subfamily, are frequently mutated and/or overexpressed in several types...
3.
Sever B, Saso L, Tzoneva R, Onnis V, Ciftci H
Front Chem
. 2024 Aug;
12:1460347.
PMID: 39130801
No abstract available.
4.
Sever B, Otsuka M, Fujita M, Ciftci H
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612471
Acquired immunodeficiency syndrome (AIDS) is an enormous global health threat stemming from human immunodeficiency virus (HIV-1) infection. Up to now, the tremendous advances in combination antiretroviral therapy (cART) have shifted...
5.
Bayrak N, Sever B, Ciftci H, Otsuka M, Fujita M, Tuyun A
Biomedicines
. 2024 Jan;
12(1).
PMID: 38255157
The development of new anticancer drugs is still ongoing as a solution to the unsatisfactory results obtained by chemotherapy patients. Our previous studies on natural product-based anticancer agents led us...
6.
Guven O, Sever B, Basoglu-Unal F, Ece A, Tateishi H, Koga R, et al.
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004473
Tumor necrosis factor receptor-associated factors (TRAFs) are a protein family with a wide variety of roles and binding partners. Among them, TRAF6, a ubiquitin ligase, possesses unique receptor binding specificity...
7.
Tahara Y, Fujita M, Zhang T, Wang D, Tateishi H, Togami A, et al.
Biol Pharm Bull
. 2023 Nov;
46(11):1535-1547.
PMID: 37914356
The introduction of combined anti-retroviral therapy (cART) in 1996, along with a continual breakthrough in anti-human immunodeficiency virus-1 (HIV-1) drugs, has improved the life expectancies of HIV-1-infected individuals. However, the...
8.
Atalay N, Akcan E, Gul M, Ayan E, Destan E, Ertem F, et al.
Turk J Biol
. 2023 Aug;
47(1):1-13.
PMID: 37529114
X-ray crystallography is a robust and powerful structural biology technique that provides high-resolution atomic structures of biomacromolecules. Scientists use this technique to unravel mechanistic and structural details of biological macromolecules...
9.
Ciftci H, Sever B, Kaya N, Bayrak N, Yildiz M, Yildirim H, et al.
Molecules
. 2023 Jan;
28(1).
PMID: 36615273
Colorectal cancer (CRC), breast cancer, and chronic myeloid leukemia (CML) are life-threatening malignancies worldwide. Although potent therapeutic and screening strategies have been developed so far, these cancer types are still...
10.
Ciftci H, Sever B, Bayrak N, Yildiz M, Yildirim H, Tateishi H, et al.
Pharmaceuticals (Basel)
. 2022 Oct;
15(10).
PMID: 36297378
Colorectal cancer (CRC) and breast cancer are leading causes of death globally, due to significant challenges in detection and management. The late-stage diagnosis and treatment failures require the discovery of...